Skip to main
OMER
OMER logo

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 65%
Buy 12%
Hold 18%
Sell 6%
Strong Sell 0%

Bulls say

Omeros Corp has reported promising results from its Expanded Access Program (EAP) for narsoplimab, highlighting a significant survival benefit in patients suffering from hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), with a demonstrated two- to three-fold reduction in mortality risk compared to control groups. The absence of approved alternatives in this niche market positions narsoplimab to potentially establish a strong market presence, bolstered by its statistically significant superiority in overall survival rates. Despite some skepticism regarding regulatory outcomes, the compelling clinical data and strategic market positioning support a positive outlook for Omeros's stock as the company advances toward potential product approval.

Bears say

Omeros Corporation is facing significant operational challenges, having accumulated substantial losses with no anticipated profitability for several years, necessitating further capital to fund research and development initiatives. Concerns regarding the uncertain path to FDA approval for its drug candidate narsoplimab, coupled with limited clinical data from a small trial and a prolonged period since the complete response letter without new data, contribute to skepticism about the company's future. Additionally, the indication of a "going concern" in its 3Q24 financial report heightens apprehensions regarding the viability of Omeros's business model and prospects.

Omeros (OMER) has been analyzed by 17 analysts, with a consensus rating of Buy. 65% of analysts recommend a Strong Buy, 12% recommend Buy, 18% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Buy based on their latest research and market trends.

According to 17 analysts, Omeros (OMER) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.